Table 1.
Demographics and baseline characteristics of Japanese patients with relapsed or refractory mantle cell lymphoma treated with ibrutinib (all treated population, n = 16)
| Items | Statistics, N = 16 |
|---|---|
| Age, years, n (%) | |
| <65 | 4 (25.0) |
| ≥65 | 12 (75.0) |
| <70 | 7 (43.8) |
| ≥70 | 9 (56.3) |
| Median (range) | 72.0 (55–83) |
| Sex, n (%) | |
| Male | 12 (75.0) |
| Weight, kg | |
| Mean (SD) | 58.34 (11.59) |
| Median (range) | 55.3 (38.4–85.0) |
| Duration of disease, months | |
| Mean (SD) | 59.84 (35.563) |
| Median (range) | 50.64 (9.7–118.0) |
| Number of prior regimens, n (%) | |
| 1 | 6 (37.5) |
| 2 | 2 (12.5) |
| ≥3 | 8 (50.0) |
| Mean (SD) | 2.3 (1.2) |
| Median (range) | 2.5 (1–4) |
| ECOG PS, n (%) | |
| 0 | 12 (75.0) |
| 1 | 4 (25.0) |
ECOG PS, Eastern Cooperative Oncology Group performance status.